Ispire Technology Inc. Expands Operations with Approval to Manufacture Nicotine Products in Malaysia

Reuters
22 May
Ispire Technology Inc. Expands Operations with Approval to Manufacture Nicotine Products in Malaysia

Ispire Technology Inc. has announced the approval of an interim license from the Malaysian Government, allowing the company to begin manufacturing nicotine products in Malaysia immediately. This marks a significant milestone for Ispire, as it is the first and only company to receive full authorization from both Federal and State authorities for the export, import, and production of nicotine products in the country. The Malaysian facility is set to expand its capacity from six to 80 production lines. Co-CEO Michael Wang emphasized that this development positions Ispire as a leading international provider of vaping hardware and helps de-risk their production strategy by diversifying their production base. The company anticipates receiving a final license in the coming months, which will complete their regulatory requirements in Malaysia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ispire Technology Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN94082) on May 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10